Boundless Bio hands Nasdaq listing to Serapha Bio in reverse merger with $230M in financing; CARsgen wins world's first CAR-T approval for solid tumors; plus uniQure, MoonLake, Definium, Versant, Corxel and US WorldMeds.
Plus news about Definium Therapeutics, uniQure, MoonLake Immunotherapeutics, Versant Ventures, Corxel Pharmaceuticals and US WorldMeds.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Sangamo holds a bankruptcy sale; VCs back a China-linked Beam competitor
CARsgen makes history as China approves world's first CAR-T therapy for solid tumors
CARsgen Announces Approval of Satri-cel, the World's First CAR T-Cell Therapy Product for Solid Tumors
China Approves World’s First CAR-T Therapy for Solid Tumors
Another big deal, another sign biotech M&A is back
Degron Therapeutics has collected an additional $40 million for its molecular glue degrader platform; CREATE Medicines raises…
Pfizer CFO exits; GSK wins FDA nod for oral UTI drug; Apellis trial paused; plus Mersana ADC dropped, TORL ADC data, Corcept…
Legend Biotech’s long-awaited first showing of in vivo CAR-T data is here, fueling momentum in the growing field.
Eli Lilly and Astellas will be the lead bidders at an auction for Sangamo assets. Elsewhere, an investor syndicate committed $230…
The world’s first CAR-T therapy for solid tumors has passed muster in China, with the country's National Medical Products…
Diamantas takes the reins, Regenxbio stakes claim in Duchenne gene therapy, and more biotech news from The Readout
